• Antipyrine (1,5-dimethyl-2-phenylpyrazol-3-one): Benchmark i

  2026-05-30

  Antipyrine is a high-purity analgesic and antipyretic agent widely used as a benchmark compound in pain relief research and blood-brain barrier permeability studies. Its exceptional solubility and stability, as supplied by APExBIO, facilitate robust pharmacokinetic and drug metabolism experiments. This article details evidence-backed protocols, clarifies common misconceptions, and positions Antipyrine as an indispensable reference in CNS drug discovery workflows.

• EZ Cap™ Cy5 EGFP mRNA (5-moUTP): Dual-Fluorescence Delivery

  2026-05-29

  EZ Cap™ Cy5 EGFP mRNA (5-moUTP) is a dual-fluorescence, capped mRNA reagent enabling real-time tracking of delivery and translation efficiency. Its Cap 1 structure and 5-methoxyuridine modifications improve stability and reduce innate immune activation. This product sets a benchmark for quantitative gene delivery assays in advanced cellular research.

• Filipin III: Strategic Cholesterol Visualization for Transla

  2026-05-29

  This thought-leadership article explores the mechanistic role of Filipin III, a polyene macrolide antibiotic, in cholesterol detection and membrane biology. Blending foundational biochemical insights, recent translational research, and competitive landscape analysis, it provides strategic guidance for investigators seeking to interrogate cholesterol-driven pathology—especially in the context of pulmonary fibrosis and emerging metabolic disease models. The discussion synthesizes advanced imaging approaches, protocol recommendations, and a critical review of current and future directions, positioning APExBIO’s Filipin III as an essential tool for next-generation translational studies.

• Puromycin Dihydrochloride: Precision Selection and Translati

  2026-05-28

  Explore the dual utility of Puromycin dihydrochloride as an aminonucleoside antibiotic for precise cell selection and as a probe into translational control. This article uniquely analyzes protocol nuances and integrates new insights from cancer biology to guide advanced applications.

• EZH2 Inhibitors for HPV-Associated Cervical Cancer: Evidence

  2026-05-28

  The referenced study demonstrates that EZH2 inhibitors, including EPZ-6438, effectively suppress HPV-driven cervical cancer cell proliferation and induce apoptosis, with a notable impact on HPV16+ cell models. These findings highlight the therapeutic promise of targeting the PRC2 pathway in HPV-associated malignancies and provide a foundation for future translational research in epigenetic cancer therapy.

• Rottlerin (B6803): Reliable PKC Inhibition for Cell Assays

  2026-05-27

  This article delivers scenario-driven, evidence-based guidance for using Rottlerin (SKU B6803) as a selective PKC inhibitor in cell viability, proliferation, and cytotoxicity assays. By addressing real laboratory challenges, it demonstrates how APExBIO's Rottlerin enables reproducible, data-backed modulation of signaling pathways relevant to cancer, apoptosis, and viral entry studies.

• Necrostatin 2 (Nec-2): Potent RIPK2 Inhibition in Necroptosi

  2026-05-27

  Necrostatin 2 (Nec-2) is a nanomolar-range, selective inhibitor of RIPK2 that enables precise necroptosis inhibition for cell death pathway research. Its high potency and stability features make it a cornerstone for dissecting programmed necrotic cell death, especially in models of ischemic stroke. This dossier details its mechanism, benchmarks, and integration protocols.

• Innovating Quantitative mRNA Delivery: EZ Cap™ Cy5 EGFP mRNA

  2026-05-26

  Explore how EZ Cap™ Cy5 EGFP mRNA (5-moUTP) enables dual-fluorescence, quantitative mRNA delivery and translation efficiency assays. This article reveals unique insights into immune evasion, nanoparticle-mediated delivery, and practical protocol advances for advanced gene function studies.

• Chloroquine and COVID-19: Lessons for Antiviral Drug Evaluat

  2026-05-26

  Touret and de Lamballerie's analysis critically reviews the evidence for chloroquine’s antiviral activity and its relevance to COVID-19. The paper highlights discrepancies between in vitro efficacy and in vivo clinical outcomes, urging caution in translating laboratory findings into therapeutic strategies.

• CDK1 Inhibition by Oxaliplatin Sensitizes Gastric Cancer to

  2026-05-25

  This study uncovers how oxaliplatin resistance in gastric cancer is driven by PARP1 and demonstrates that oxaliplatin impairs CDK1 activity, making BRCA-proficient tumors more responsive to PARP inhibitors. These findings suggest a rational combination strategy to overcome chemotherapy resistance and improve therapeutic outcomes.

• Naloxone Hydrochloride: Mechanisms and Strategy for Translat

  2026-05-25

  This thought-leadership article explores the evolving landscape of naloxone hydrochloride as a tool for translational research. We integrate mechanistic insights on opioid receptor antagonism, neural stem cell proliferation, and immune modulation, drawing on both foundational studies and the latest competitive benchmarks. Strategic guidance is provided for researchers aiming to leverage high-purity naloxone hydrochloride (SKU B8208) from APExBIO in neurobiological, addiction, and immunological assays. The article advances the discourse beyond overdose intervention, positioning naloxone as a cornerstone for dissecting opioid signaling and neural plasticity.

• DAPT (GSI-IX): Optimizing Notch Pathway and Organoid Researc

  2026-05-24

  DAPT (GSI-IX) empowers researchers to dissect Notch signaling with precision in disease models, organoid systems, and cell-based assays. This article translates cutting-edge workflows and troubleshooting strategies into actionable guidance for maximizing γ-secretase inhibition and experimental reliability.

• CCG-1423: Advancing RhoA Inhibitor Strategy in Translational

  2026-05-23

  Explore the mechanistic and strategic foundations for deploying CCG-1423, a potent RhoA inhibitor, in translational research. This article connects emerging virology findings with cancer biology, details protocol applications, and offers translational guidance, highlighting how CCG-1423 from APExBIO enables reproducible and insightful interrogation of RhoA/ROCK signaling.

• Proteomic Shifts in Lung Adenocarcinoma after HSP90 Inhibiti

  2026-05-22

  This study uses proteomic profiling to reveal how HSP90 inhibition alters signaling and metabolic pathways in lung adenocarcinoma cells. Findings highlight new candidate biomarkers and clarify the molecular consequences of targeting chaperone networks, informing further research on apoptosis and cancer therapy resistance.

• Metformin-Induced EDH in Colitis: Mechanisms and Implication

  2026-05-22

  This study reveals that metformin induces vasorelaxation in mesenteric arterioles via endothelium-dependent hyperpolarization (EDH), a mechanism that remains robust even during ulcerative colitis. By delineating calcium signaling pathways and demonstrating metformin's ability to restore impaired acetylcholine responses, the work provides actionable insights for cardiovascular and inflammatory research.

15159 records 1/1011 page Next 12345 下5页 Last page